Ulcerative Colitis

Sun Pharmaceutical Industries received FDA approval of its abbreviated new drug application for mesalamine extended-release capsules indicated for use in ulcerative colitis, according to a press release.

Anti-tumor necrosis factor therapy had reduced efficacy and safety for bio-naive patients with older-onset inflammatory bowel disease compared with younger patients, according to a study published in Scientific Reports.

NAPLES, Florida — Asad Ur Rahman, MD, a gastroenterologist at Cleveland Clinic Florida, spoke with Healio about highlights from three presentations he attended at the 2022 ACG/FGS Spring Symposium.

Intermittent fasting during the month of Ramadan was associated with deterioration of clinical parameters in a small group of patients with ulcerative colitis, according to research published in BMC Gastroenterology.

Individuals who have a sibling with inflammatory bowel disease had a fourfold-increased risk for IBD compared with the general population, according to research published in Alimentary Pharmacology & Therapeutics.

A systematic review and meta-analysis revealed a high prevalence of fatigue among patients with inflammatory bowel disease, according to research published in Clinical Gastroenterology and Hepatology.

A comprehensive review of data showed that two doses of a SARS-CoV-2 vaccine were safe and effective in patients with inflammatory bowel disease, according to a report in Alimentary Pharmacology & Therapeutics.

NAPLES, Florida — Jennifer L. Seminerio, MD, spoke with Healio about key takeaways from her 2022 ACG/FGS Spring Symposium presentation, which focused on treatment for mild to moderate ulcerative colitis and Crohn’s disease.

Preliminary data from the COMPASS-IBD study showed an interdisciplinary care model improved psychosocial outcome values among patients with inflammatory bowel disease.

In a Healio video exclusive, Jan Wehkamp, MD, global strategy leader for gastroenterology at Janssen Pharmaceuticals, reports key data points from the company’s 3-year, phase 3 UNIFI study.